tirzepatide microdosing protocol I'm starting a new longevity protocol: Tirzepatide, a dual GLP-1/GIP receptor agonist. Here is the existing evidence, my protocol, measurement plan, and what I expect to achieve by this intervention. 🧵 Tirzepatide Microdosing: The Growing Off-Label

The main reason: the lack of randomized controlled clinical trials in humans

In parallel, other studies have explored the broader biological functions of SIRT7, particularly its role in immune regulation and mitochondrial homeostasis

You might notice severe pain in the upper stomach area

If youre a dermatology practitioner, I recommend the review article

Therefore, we proposed to require hospitals to report four new data elements when the payer-specific negotiated charge is based on a percentage or algorithmthe median allowed amount (which would replace the estimated allowed amount data element), the 10th percentile allowed amount, the 90th percentile allowed amount, and the count of allowed amounts